Literature DB >> 2153443

DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues.

L Dusre1, S Rajagopalan, H M Eliot, J M Covey, B K Sinha.   

Abstract

A subline of the human breast tumor cell line (MCF-7), selected for resistance to Adriamycin and having the multidrug resistance phenotype, also developed significant cross-resistance to mitomycin C and its two analogues, BMY 25282 and BMY 25067. Because mitomycin C and the analogues contain both quinone and aziridine moieties, the mechanism of tumor cell kill is thought to involve alkylation and cross-linking of DNA molecules, hence they are not expected to show cross-resistance to cells selected for resistance to a DNA intercalator. Studies to understand this novel observation show that the resistant MCF-7 cells form significantly less hydroxyl radical and DNA cross-linking in the presence of mitomycin C and BMY 25282 than the sensitive cells. Although BMY 25067 formed less free radicals in the resistant cells, similar to the other two drugs, the formation of DNA cross-links was identical in both cell lines, indicating a somewhat different mechanism of tumor cell kill by this analogue. DNA cross-link formation increased slightly with time in the sensitive cells while there was a small decrease in the resistant cells. This difference in the formation of toxic intermediates appeared to result from enhanced detoxification of reactive species (hydrogen peroxide and alkylating intermediates) as a result of significantly higher glutathione peroxidase (14-fold) and glutathione S-transferase (44-fold) activities in the resistant cell line. These events, i.e., free radical formation and DNA alkylation, showed a good correlation with the cytotoxicity in drug-sensitive cells, indicating that both mechanisms contribute to cell killing of human breast tumor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153443

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Modulation of mitomycin C-induced multidrug resistance in vitro.

Authors:  R T Dorr; J D Liddil
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.

Authors:  Dean Lim; Robert J Morgan; Steven Akman; Kim Margolin; Brian I Carr; Lucille Leong; Oluwole Odujinrin; James H Doroshow
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

4.  Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.

Authors:  W C Yen; T Schmittgen; J L Au
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase.

Authors:  M F Belcourt; W F Hodnick; S Rockwell; A C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

6.  Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial.

Authors:  M Tetef; K Margolin; C Ahn; S Akman; W Chow; P Coluzzi; L Leong; R J Morgan; J Raschko; S Shibata
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Phase I study of mitomycin C and menadione in advanced solid tumors.

Authors:  K A Margolin; S A Akman; L A Leong; R J Morgan; G Somlo; J W Raschko; C Ahn; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Mitomycin C and menadione for the treatment of lung cancer: a phase II trial.

Authors:  M Tetef; K Margolin; C Ahn; S Akman; W Chow; L Leong; R J Morgan; J Raschko; G Somlo; J H Doroshow
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

9.  Characterization of a BMS-181174-resistant human bladder cancer cell line.

Authors:  H Xia; R J Bleicher; X Hu; S K Srivastava; V Gupta; H A Zaren; S V Singh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Oxidative stress-related mechanisms are associated with xenobiotics exerting excess toxicity to Fanconi anemia cells.

Authors:  Giovanni Pagano; Paola Manini; Debasis Bagchi
Journal:  Environ Health Perspect       Date:  2003-11       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.